Michael E Hochman

50 Studies Every Neurologist Should Know

Herausgeber: Hwang, David Y; Greer, David M

• Broschiertes Buch

Produktbeschreibung

50 Studies Every Neurologist Should Know presents summaries and analyses of the fifty clinical trials that have shaped the current practice of neurology. Every subspecialty is covered, with special emphasis on neurocritical care and vascular neurology.

Produktdetails

• Verlag: Oxford University Press, USA
• Seitenzahl: 376
• Erscheinungstermin: 11. Mai 2016
• Englisch
• Abmessung: 230mm x 153mm x 21mm
• Gewicht: 510g
• ISBN-13: 9780199377527
• ISBN-10: 0199377529
• Artikelnr.: 47871145

Autorenporträt

David Y. Hwang is the Assistant Professor of Neurology in the Division of Neurocritical Care and Emergency Neurology at Yale University School of Medicine which is located in New Haven, Connecticut. David M. Greer is the The Zimmerman and Spinelli Professor and Vice Chairman of the Department of Neurology at Yale University School of Medicine which is located in New Haven, Connecticut.

Inhaltsangabe

* Section I: Behavioral Neurology
* 1. Cholinesterase Inhibitors for Alzheimer's Disease
* 2. Memantine for Alzheimer's Disease
* Section II: Epilepsy
* 3. Lorazepam for Generalized Status Epilepticus
* 4. Lamotrigine for Partial Epilepsy: Arm A of the SANAD Trial
* 5. Valproate for Generalized and Unclassifiable Epilepsy: Arm B of
the SANAD Trial
* Section III: Headache
* 6. Sumatriptan for Acute Migraine
* Section IV: Neuroinfectious Disease
* 7. Steroids for Bell's Palsy
* 8. Steroids for Acute Bacterial Meningitis
* Section V: Movement Disorders
* 9. Levadopa for Parkinson's Disease
* 10. Deep-Brain Stimulation for Parkinson's Disease
* Section VI: Multiple Sclerosis
* 11. Oral vs. IV Steroids for Acute Relapses of Multiple Sclerosis
* 12. Interferon Beta-1a for a First Demyelinating Event: The CHAMPS
Trial
* 13. Glatiramer Acetate for Clinically Isolated Syndrome: The PreCISe
Trial
* 14. Natalizumab for Relapsing Multiple Sclerosis: The SENTINEL Trial
* 15. Fingolimod for Relapsing Multiple Sclerosis: The TRANSFORMS Trial
* 16. Oral BG-12 for Relapsing-Remitting Multiple Sclerosis, Part I:
The DEFINE Trial17. Oral BG-12 for Relapsing-Remitting Multiple
Sclerosis, Part II: The CONFIRM Trial
* Section VII: Neurocritical Care
* 18. Therapeutic Hypothermia for Cardiac Arrest, Part I: The HACA
Trial
* 19. Therapeutic Hypothermia for Cardiac Arrest, Part II: The
Australian Trial
* 20. Decompressive Craniectomy for Diffuse Traumatic Brain Injury: The
DECRA Trial
* 21. Nimodipine for Subarachnoid Hemorrhage
* Section VIII: Neuromuscular Disease
* 22. IVIG vs. Plasma Exchange for Guillain-Barre Syndrome
* 23. IVIG vs. Plasma Exchange for Myasthenia Gravis
* 24. Riluzole for Amyotrophic Lateral Sclerosis
* Section IX: Neuro-Oncology
* 25. Radiotherapy Plus Temozolomide for Glioblastoma
* 26. Methylated MGMT Gene Promoter and Response to Temozolomide for
Glioblastoma
* Section X: Neuro-Ophthalmology
* 27. Steroids for Acute Optic Neuritis: The Optic Neuritis Treatment
Trial
* Section XI: Neuro-Otology
* 28. The Epley Maneuver for Benign Paroxysmal Positional Vertigo
* Section XII: Sleep
* 29. Modafinil for Narcolepsy
* 30. Continuous Dopamine Agonist for Restless Legs Syndrome
* Section XIII: Spine Disorders
* 31. Early Surgery for Sciatica
* 32. Surgery for Lumbar Degenerative Spondylolisthesis: The SPORT
Trial
* 33. Steroids vs. No Steroids for Acute Spinal Cord Injury: The NASCIS
II Trial
* Section XIV: Vascular Neurology
* 34. IV Thrombolysis 3 Hours After an Acute Ischemic Stroke: The NINDS
Trial
* 35. IV Thrombolysis 3 to 4.5 Hours After an Acute Ischemic Stroke:
The ECASS III Trial
* 36. Endovascular Therapy for Acute Ischemic Stroke, Part I
(Intra-arterial Thrombolysis): The PROACT II Trial
* 37. Endovascular Therapy for Acute Ischemic Stroke, Part II (After IV
Thrombolysis): The IMS III Trial
* 38. Endovascular Therapy for Acute Ischemic Stroke, Part III (Using
Neuroimaging to Select Patients): The MR RESCUE Trial
* 39. Endovascular Therapy for Acute Ischemic Stroke, Part IV (Clinical
Trial Success): The MR CLEAN Trial
* 40. Carotid Endarterectomy for Symptomatic High-Grade Carotid
Stenosis: The NASCET Trial, Part I
* 41. Carotid Endarterectomy for Symptomatic Moderate Carotid Stenosis:
The NASCET Trial, Part II
* 42. Carotid Endarterectomy for Asymptomatic Carotid Stenosis: The
ACAS Trial
* 43. Early Aspirin for Acute Ischemic Stroke: The CAST Trial
* 44. Aspirin vs. Heparin for Acute Ischemic Stroke: The IST Trial
* 45. Dipyridamole and Asprin for Secondary Stroke Prevention: The
ESPS-2 Trial
* 46. High-Dose Atorvastatin After Stroke or Transient Ischemic Attack:
The SPARCL Trial
* 47. Adjusted-Dose Warfarin for Stroke Prevention in High-Risk Atrial
Fibrillation Patients: The SPAF III Trial
* 48. Dabigatran for Stroke Prevention in Atrial Fibrillation Patients:
The RE-LY Trial
* 49. Apixaban for Stroke Prevention in Atrial Fibrillation Patients:
The ARISTOTLE Trial
* 50. Rivaroxaban for Stroke Prevention in Atrial Fibrillation
Patients: The ROCKET AF Trial